Altered Decorin Leads to Disrupted Endothelial Cell Function: A Possible Mechanism in the Pathogenesis of Fetal Growth Restriction?

Chui A¹, Murthi P²,³, Gunatillake T¹,³, Brennecke S.P²,³, Ignjatovic V⁴,⁵,⁶, Monagle P.T⁴,⁵,⁶, Whitelock J.M⁷, and Said J.M¹

¹NorthWest Academic Centre, The University of Melbourne and Sunshine Hospital, St Albans 3021, Australia. ²Department of Perinatal Medicine, Pregnancy Research Centre, The Royal Women’s Hospital and ³Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville 3052, Australia. ⁴Murdoch Children’s Research Institute and ⁵Department of Clinical Haematology and ⁶Department of Paediatrics, The Royal Children’s Hospital and The University of Melbourne, Parkville 3052, Australia. ⁷Graduate School of Biomedical Engineering, University of New South Wales, Kensington 2033, Australia.

Corresponding author:
Dr. Amy Chui
NorthWest Academic Centre
The University of Melbourne and Sunshine Hospital
PO Box 294, 176 Furlong Road
St Albans 3021, Australia
Tel: +61 3 8395 8088
Fax: +61 3 8395 8258
Email: akl.chui83@gmail.com
Abstract

Objective: Fetal growth restriction (FGR) is a key cause of adverse pregnancy outcome where maternal and fetal factors are identified as contributing to this condition. Idiopathic FGR is associated with altered vascular endothelial cell functions. Decorin (DCN) has important roles in the regulation of endothelial cell functions in vascular environments. DCN expression is reduced in FGR. The objectives were to determine the functional consequences of reduced DCN in a human microvascular endothelial cell line model (HMVEC), and to determine downstream targets of DCN and their expression in primary placental microvascular endothelial cells (PLECs) from control and FGR-affected placentae.

Approach: Short-interference RNA was used to reduce DCN expression in HMVECs and the effect on proliferation, angiogenesis and thrombin generation was determined. A Growth Factor PCR Array was used to identify downstream targets of DCN. The expression of target genes in control and FGR PLECs was performed.

Results: DCN reduction decreased proliferation and angiogenesis but increased thrombin generation with no effect on apoptosis. The array identified three targets of DCN: FGF17, IL18 and MSTN. Validation of target genes confirmed decreased expression of VEGFA, MMP9, EGFR1, IGFR1 and PLGF in HMVECs and PLECs from control and FGR pregnancies.

Conclusions: Reduction of DCN in vascular endothelial cells leads to disrupted cell functions. The targets of DCN include genes that play important roles in angiogenesis and cellular growth. Therefore, differential expression of these may contribute to the pathogenesis of FGR and disease states in other microvascular circulations.

Key words: endothelial function; thrombosis; angiogenesis; gene expression; regulation
Introduction

Fetal growth restriction (FGR) is defined as a neonatal birth-weight less than 10th percentile for gestation together with evidence of fetal welfare compromise such as reduced amniotic fluid volume, increased head to abdomen circumference ratio and abnormal umbilical artery blood flow patterns [1]. FGR greatly increases the risk of perinatal complications including: fetal compromise in labour, fetal death in utero, neonatal morbidity and neonatal death [2-4]. Live born infants from pregnancies complicated by FGR have an increased risk of paediatric disorders such as cerebral dysfunction and learning difficulties, and of developing chronic adult onset diseases including: cardiovascular complications, type II diabetes, hypertension and ischemic heart disease [5-7]. Idiopathic FGR accounts for 70% of all cases of FGR and is believed to be associated with uteroplacental insufficiency [8], abnormal umbilical artery Doppler velocimetry [9], oligohydramnios [10] and fetal growth asymmetry [11]. Placental insufficiency may result from various factors including: constriction of the placental blood vessels due to reduction in vasodilator activity [12], incomplete cytotrophoblastic invasion of the maternal spiral arteries [13] or maldevelopment of the placental villous structures [14]. These factors result in increased resistance to blood flow within the placenta in both the maternal and fetal circulations, ultimately resulting in fetal hypoxia and acidosis.

Normal pregnancy represents a hypercoagulable state characterised by profound changes in haemostasis, such as, increased concentration of pro-coagulant factors, decreased anticoagulant activity and diminished fibrinolytic activity [15]. These changes result in increased thrombin generation in maternal plasma and ultimately, increased fibrin formation. These changes in haemostasis ensure the rapid and effective control of bleeding at the time of placental separation during delivery [15]. On the other hand, these changes may also predispose pregnant women to thrombosis and placental vascular complications. Despite this, thrombotic events are rare in uncomplicated pregnancies [16], indicating that thrombin generation must be tightly regulated in this scenario. In contrast, histological examinations of placentae from FGR pregnancies demonstrate increased fibrin deposition and thrombi in the vasculature, including uteroplacental and intervillous thrombosis, perivillous fibrin deposits and villous stem artery thrombosis [16], indicating an increase in overall thrombin activation [17]. The cause of the coagulation disturbance and increased placental thrombosis observed in idiopathic FGR pregnancies is unknown. However, since thrombin generation is significantly increased during normal pregnancy compared to the non-pregnant state [18], the excess thrombin is likely to be generated predominantly by the placenta, as demonstrated by decreased thrombin generation following placental separation during delivery [19].

Proteoglycans (PGs) are macromolecules comprising a core protein and at least one negatively charged polysaccharide glycosaminoglycan (GAG) side chain. The small leucine-rich proteoglycan (SLRP) family constitutes a network of signal regulation: being mostly extracellular, they are upstream of multiple signalling cascades, a major conduit
of information for cellular responses and modulators of distinct pathways [20]. Decorin (DCN) belongs to the Class I SLRPs and can be substituted with one of either chondroitin or dermatan sulphate glycosaminoglycan (GAG) side chains. Previously, we have demonstrated an association between reduced placental DCN expression and FGR [21], and propose that due to the many actions of DCN in vivo, this reduction contributes to the pathogenesis of FGR [22]. DCN and its side chain are involved in multiple biological functions such as, anticoagulation by binding to heparan cofactor II through a highly charged sequence [23], regulation of angiogenic growth factors such as, epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) [24] as well as regulation of basic cellular functions such as proliferation, migration and invasion [25, 26]. Mouse knockout models of DCN demonstrate a range of pregnancy disorders including: pre-term birth [27], dystocia and delayed labour onset [28], as well as developmental anomalies in the offspring including: osteoporosis, osteoarthritis and corneal disease [29].

Since disturbances in many of these biological functions have been demonstrated in the pathogenesis of FGR, DCN may in fact play a major role in the pathogenesis of FGR. Therefore, in the present study, we investigated the effect of reduced DCN gene expression on the function of microvascular endothelial cells. We also determined the down-stream target genes of DCN, in a placental microvascular endothelial cell environment and further validated the expression of these targets in control and FGR-affected placentae.
Materials and methods (for additional methodology please refer to Supplementary Data)

Cell lines
The human microvascular endothelial primary cells from neonatal foreskin (HMVEC) were a kind gift from A/Prof. Grant Drummond (Department of Pharmacology, Monash University).

Reduction of DCN expression by siRNA
Four independent DCN siRNA oligonucleotides were obtained as “4-For-Silencing siRNA Duplexes™” (Qiagen, Victoria, Australia). The DCN siRNAs showed no significant DNA sequence similarity to other genes in GenBank cDNA databases (data not shown).

RNA extraction and cDNA preparation
Total RNA was extracted from cultured HMVECs using PureLink RNA Mini-kits (Life sciences, Victoria, Australia), as per manufacturer’s instructions. cDNA was prepared in a two-step reaction using 2µg of total RNA.

Real-Time PCR
Quantification of DCN mRNA expression was determined by real-time PCR in an ABI Prism 7700 (Perkin-Elmer-Applied Biosystems, Victoria, Australia) as described previously [30].

Western Immunoblotting
Protein was homogenised and extracted from cultured HMVECs using RIPA Buffer (Pierce, Victoria, Australia). Immunoblotting was performed as described elsewhere [30]. The level of immunoreactive DCN protein relative to GAPDH was determined semi-quantitatively using scanning densitometry (Image Quant, New South Wales, Australia).

HMVEC cell growth using xCELLigence
HMVEC cell growth was assessed using the xCELLigence SP real-time system (Roche Diagnostics, Victoria, Australia) according to the manufacturer’s instructions. The results were analysed using the RTCA Software 1.2 (Roche Diagnostics, Victoria, Australia) and GraphPad Prism 5 (GraphPad Software, California, USA).

HMVEC network formation assays
HMVEC network formation was assessed using the μ-Slide Angiogenesis system (IBIDI, Victoria, Australia) as per manufacturer’s instructions using 10µl of neat Growth-Factor Reduced Matrigel™ (BD, Victoria, Australia). Photomicrographs of entire wells were taken in triplicates and branch points were counted by Wimasis Image Analysis.

Thrombin Generation Assays
HMVECs were plated into 96 well plates at a density of 5000 cells per well and transfected with DCN siRNAs and controls for 48h. Venous blood was collected from
healthy blood donors (n=40). Measurement of endogenous thrombin potential (ETP) by
Calibrated Automated Thrombogram (CAT, Thrombinoscope, Stago Diagnostica, 
Victoria, Australia) was performed according to manufacturer’s instructions. The ETP 
(nM/minute) was calculated using the Thrombinoscope software version 3.0.0.29.

**Human Growth Factors PCR Array**
The “Human Growth Factor” Taqman PCR array (Applied Biosystems, Victoria, Australia)
for gene profiling was used to screen for downstream target genes of DCN, according to 
manufacturer’s instructions. Candidate genes were prioritised based on level of gene
expression i.e. at least 2-fold change in mRNA expression in siRNA treated cells when
compared with NC.

**Feto-placental microvascular endothelial cell (PLEC) isolation**
Placentae from pregnancies complicated by idiopathic FGR (n=3) and gestation-
matched control (n=3) pregnancies were collected with informed patient consent and
approval from the Human Research and Ethics Committees of The Royal Women’s
Hospital, Melbourne. Ultrasound data were used to prospectively identify pregnancies
complicated by FGR. The inclusion criteria of patients included in this study has been
previously published [21].

Isolation of PLEC was undertaken according to the published methods of Dunk et al.
2012, using placental biopsies obtained from fresh placenta [31].

**Data Analysis**
All data in this study are described as mean±SEM and analysed by the GraphPad Prism
6 statistical software (GraphPad Software, California, USA). One-Way ANOVA was
used to assess the differences in DCN mRNA and protein expression between siRNA-
treated and control groups as well as in HMVEC functional assay studies. The Mann-
Whitney U test was used to analyse differences in gene expression between whole
placenta and PLECs from control and FGR-affected placentae. A probability value of
<0.05 was considered significant.

**Results**
Reduced DCN mRNA and protein expression following siRNA transfection in
HMVECs
Four independent siRNAs (designated as siRNA1-4), were designed to reduce DCN
expression in HMVECs. A non-siRNA transfected control (Mock) and a non-specific
siRNA transfected control were used as negative controls. Fig 1A revealed that
treatment with siRNA2 and siRNA3 significantly reduced DCN mRNA expression
compared to both the Mock and NC controls (Mock: 0.90±0.14 and NC: 0.59±0.02 vs.
s2: 0.01±0.001 and s3: 0.05±0.01, p<0.005, n=18, One-Way ANOVA) at 48h after
transfection. A representative immunoblot for DCN (60kDa) protein is shown in Fig 1B
for Mock, NC, siRNA2 and siRNA3, with the corresponding GAPDH. Semi-quantitative
densitometry analysis revealed a decrease in immunoreactive DCN protein abundance
in HMVECs treated with siRNA2 or siRNA3 compared with both the Mock and NC controls (Mock: 1.76±0.05 and NC: 1.57±0.05 vs. s2: 0.10±0.01 and s3: 0.08±0.1, p<0.05, n=3, One-Way ANOVA, Fig 1C).

**Reduced DCN expression does not increase HMVEC apoptosis**

In order to determine that the reduction in DCN expression was not due to apoptosis as a result of treatment with siRNAs, the mRNA expression of three common apoptotic markers were analysed. Real-time PCR revealed that the mRNA expression of BCL2, p53 and CASPASE3 were not significantly different compared to the Mock or the NC controls (p>0.05, n=18, One-Way ANOVA, data not shown).

**Reduced DCN expression decreases HMVEC proliferation and network formation but increases thrombin generation**

The effect on HMVEC proliferation after 48h DCN siRNA2 or siRNA3 treatment was determined using the xCELLigence system. Optimisation experiments confirmed that 5000 cells per well was the optimal density of cells to allow uninhibited cell proliferation (data not shown). Fig 2A is a representative graph showing the cell index of HMVECs treated with siRNA compared to Mock or NC controls over 72h. At 48h post-siRNA transfection, the proliferation potential of the HMVECs were significantly decreased following DCN reduction compared to both controls (Mock: 1.92±0.04 and NC: 1.94±0.02 vs. s2: 1.19±0.06 and s3: 1.25±0.26, p<0.05, n=18, One-Way ANOVA, Fig 2B).

The ability of HMVECs to form networks after DCN gene reduction was determined using the µ-slide Angiogenesis system by IBIDI. Optimisation experiments to determine the optimal Growth-Factor Reduced Matrigel™ concentration and cell density were performed (data not shown). Following incubation for 48h, the cells were stained with calcien. Fig 2C shows representative images at 100x magnification taken after 48h DCN siRNA transfection and reveals a qualitative decrease in HMVEC network formation compared to Mock or NC controls. Branch points were analysed and revealed that the network formation potential of HMVECs were significantly decreased following DCN gene reduction compared to both controls (Mock: 9.0±0.62 and NC: 9.27±0.63 vs. s2: 2.36±0.59 and s3: 4.09±0.89, p<0.01, n=18, One-Way ANOVA, Fig 2D).

The ETP of the HMVECs following the reduction in DCN gene expression was determined using the CAT system. A representative thrombin generation curve following reduction in DCN gene expression in HMVECs is depicted in Fig 2E. Reduction of DCN expression by siRNA3 resulted in a significant increase in the ETP of the HMVECs compared with the Mock and NC controls (Mock: 1757.83±152.98 and NC: 1749.28±40.66 vs. s3: 1903.44±107.33, p<0.03, n=9, One-Way ANOVA, Fig 2F).

**Identification of DCN downstream target genes**

HMVECs were transfected with a NC control and siRNA3 and the “Human Growth Factors” Taqman PCR array was used to identify potential downstream target genes of DCN. The relative mRNA expression of the 84 genes after DCN mRNA and protein down-regulation is shown in Fig 3. The Y-axis represents the fold change for each of the
84 genes normalised to the average expression of the five housekeeping genes included in the array. Genes that had an expression level above the positive two-fold change as indicated by a red line, was classified as genes with a fold increase. Conversely, genes that had an expression level below the negative two-fold change green line were classified as genes with a fold decrease in gene expression. The screening array identified three potential candidate downstream target genes of DCN in HMVECs. These are fibroblast growth factor 17 (FGF17) with a fold increase of 2.4, interleukin 18 (IL18) with a fold decrease of 3.3 and myostatin (MSTN) with a fold decrease of -2.8.

The mRNA expression of FGF17, IL18, and MSTN were further validated in HMVECs transfected with DCN siRNA independently (Fig 4). Increased expression of FGF17 (Mock: 1.04±0.19 and NC: 1.29±0.14 vs. s2: 4.62±0.76 and s3: 4.77±0.46, p<0.05, n=9, One-Way ANOVA) and decreased expression of MSTN (Mock: 1.00±0.06 and NC: 1.81±0.18 vs. s2: 0.51±0.19 and s3: 0.43±0.09, p<0.05, n=9, One-Way ANOVA) was confirmed. IL18 was not differentially expressed in DCN reduced HMVECs under independent validation (data not shown).

The mRNA expression of known target genes of DCN from the published literature was also investigated in HMVECs following DCN gene reduction. As shown in Fig 5, the expression of VEGFA (Mock: 1.21±0.11 and NC: 1.01±0.10 vs. s2: 0.40±0.05 and s3: 0.18±0.07, p<0.05, n=9, One-Way ANOVA), MMP9 (Mock: 1.19±0.21 and NC: 0.85±0.11 vs. s2: 0.14±0.01 and s3: 0.03±0.02, p<0.01, n=9, One-Way ANOVA), EGFR1 (Mock: 0.76±0.22 and NC: 1.00±0.01 vs. s2: 0.26±0.03 and s3: 0.18±0.03, p<0.05, n=9, One-Way ANOVA), IGFR1 (Mock: 0.80±0.06 and NC: 1.01±0.11 vs. s2: 0.41±0.06 and s3: 0.29±0.0.03, p<0.05, n=9, One-Way ANOVA) and PLGF (Mock: 1.07±0.27 and NC: 1.96±0.06 vs. s2: 0.23±0.02 and s3: 0.28±0.05, p<0.03, n=9, One-Way ANOVA) were significantly reduced following treatment with DCN siRNA2 or siRNA3 compared with the Mock or NC controls. The mRNA expression of MMP2, HIF1A, Thrombospondin1, TIMP3, TLR2 and TLR4 were not significantly different between the two groups (data not shown).

Validation of DCN and its downstream target genes in control and FGR-affected primary placental endothelial cells (PLECs)

The mRNA expression of DCN and its targets were validated in PLECs cultured from control and FGR-affected placentae. Shown in Fig 6A, the mRNA expression of DCN was significantly decreased in PLECs cultured from FGR-affected placenta compared with controls (Control PLEC: 1.04±0.14 vs. FGR PLEC: 0.21±0.06, p<0.003, n=3 each, Mann-Whitney U Test). In Fig 6B-F, significant decreases in mRNA expression was also observed for EGFR1 (Control PLEC: 1.04±0.11 vs. FGR PLEC: 0.26±0.06, p<0.003, n=3 each, Mann-Whitney U Test), IGFR1 (Control PLEC: 1.05±0.15 vs. FGR PLEC: 0.45±0.05, p<0.005, n=3 each, Mann-Whitney U Test), PLGF (Control PLEC: 1.18±0.32 vs. FGR PLEC: 0.32±0.12, p<0.05, n=3 each, Mann-Whitney U Test) and VEGFA (Control PLEC: 1.52±0.60 vs. FGR PLEC: 0.33±0.07, p<0.05, n=3 each, Mann-Whitney U Test) between control and FGR-affected PLECs. In contrast, the mRNA expression of MMP9 was significantly increased in FGR-affected PLECs compared with controls.
(Control PLEC: 1.09±0.21 vs. FGR PLEC: 2.51±0.40, p<0.03, n=3 each, Mann-Whitney U Test). These results are consistent with those observed in the previous validation experiments using HMVECs (with the exception of FGF17 and MSTN which were not expressed in PLECs).
Discussion

In this current study we focused on DCN, a small leucine-rich proteoglycan, and demonstrate for the first time that reduction of DCN gene expression in a primary human microvascular endothelial cell type (HMVEC) results in a significant decrease in HMVEC proliferation, network formation and thrombin generation. We also revealed differential expression of DCN target genes in FGR-affected primary placental microvascular endothelial cells (PLECs). The results reveal a consistency in the expression patterns of VEGFA, MMP9, EGFR1, IGFR1 and PLGF.

In tumour cells, DCN has been shown to command a powerful anti-tumorigenic signal by potently repressing and attenuating tumour cell proliferation, survival, migration and angiogenesis via binding to EGFR and IGFR [32]. In addition, DCN has also been described as an angiostatic agent in tumour cells via a reduction in VEGF and MMP9 production [33]. In extravillous trophoblast cells, DCN has been shown to be an antagonist of proliferation and migration, via suppression of VEGFR2 and EGFR1 [25], as well as extravillous differentiation and angiogenesis by blocking activation of p38 MAPK, and ERK pathways by VEGFA [34].

In this study, reduction of DCN expression resulted in decreased HMVEC proliferation and network formation, potentially due to the subsequent downstream decrease in the expression of EGFR1, IGFR1 and VEGFR. Inadequate fetal vessel angiogenesis and proliferation is consistent with histological observations of the FGR placenta [14]. Thus DCN appears to mediate a pro-angiogenic role in HMVECs and deficiency of DCN results in inhibition of angiogenesis and proliferation. Our findings are in contrast with those in the cancer literature but are supported by other studies demonstrating a pro-angiogenic and pro-proliferative response of DCN, primarily on normal, non-tumorigenic endothelial cells [35]. Furthermore, evidence suggests that DCN-deficient mice have diminished growth of vessels [36].

Despite the multiple biological actions of DCN on a variety of cell types, the nature of the cell surface receptors responsible for DCN action has remained elusive in many cases. For example, DCN was shown to interact with EGFR in a squamous cell carcinoma line, leading to the triggering of a signal cascade, and finally growth suppression associated with a retardation of EGFR recycling to the cell surface [37-41]. DCN also interacts with IGFR in endothelial cells, leading to its phosphorylation, followed by a down-regulation of the receptor, resulting in cell survival [25]. Therefore, the dichotomous effect reported for DCN on endothelial cells and the previously described function on tumourigenesis creates a scenario where DCN may be able to differentially modulate angiogenesis.

Another plausible explanation for the diverse functions of DCN is that small leucine-rich proteoglycans undergo a dimer-monomer transition that would expose key sites involved in specific bindings; therefore their functional activity in vivo would be regulated by the structure of DCN in that particular cell type and by the intrinsic affinity of DCN for
its cognate receptor [20, 42]. In addition, the binding and function of DCN to specific receptors also depends on whether it is a GAG-bound DCN or just the core protein [43].

The differences between the cells in the previous published work are that both tumour cells and extravillous trophoblast cells are highly proliferative, invasive and angiogenic where DCN negatively regulates angiogenesis and proliferation in highly proliferative, invasive, and angiogenic environment to prevent aberrant tumour growth. However, in this study, we used HMVECs, which represents normal microvascular environment whose primary function is to form networks during vascular development. Therefore, it is possible that in a normal microvasculature environment, where a balanced level of angiogenesis and proliferation is required, DCN may act positively to regulate proliferation and angiogenesis.

Thrombin generation is a global haemostatic functional assay used widely to measure hypo- or hyper-coagulability and reflects the interplay of all haemostatic factors in plasma/blood. The ETP provides an in vitro measure of the overall ability to generate thrombin, the final crucial stage of haemostasis and is therefore, the best assessment of global haemostasis [44]. The ETP quantifies the visual differences between the thrombin generation curves and allows for statistical analysis. This study has demonstrated a modest, but statistically significant increase in thrombin generation following reduction in DCN expression in HMVECs which implies a hyper-coagulable state with DCN down-regulation. This is consistent with observations in the FGR placenta where increased intervillous thrombi are observed [9]. Delorme et al (1998) isolated and characterized the glycosaminoglycan, dermatan sulphate (DS), in term human placenta and revealed that DS was predominantly present on the protein core of DCN. Since DS catalyzes the inhibition of thrombin by heparin-cofactor II [45], a reduction in DCN expression in HMVECs could result in an increase in thrombin generation [19]. Although the difference observed is small, this difference in a global setting could potentially lead to significant changes to overall thrombin generation in the placental microvascular system. It is therefore plausible that the observed increase in localised placental intravascular thrombosis is due to a decrease in the expression of DCN in human FGR-affected placentae [21].

Since it appears that the molecular function of DCN is also highly dependent on the structure, function and sulfation/glycosylation sites of both the protein core and the GAG side chain [20, 46, 47], investigations into the exact structural moiety of DCN in both the control and FGR-affected placenta could reveal important information about the role of DCN in the pathogenesis of FGR.

In summary, this study has shown that reduced expression of the proteoglycan DCN in a microvascular endothelial cell line results in altered endothelial cell functions such as proliferation and network formation as well as an increase in global thrombin generation without affecting apoptosis. These alterations may be a consequence of altered growth factor expression as a result of downstream regulation by DCN or via a direct local effect of reduced DCN and dermatan sulphate abundance. These findings provide valuable insight into the endothelial milieu in the growth restricted placenta. This raises
the possibility that increased $DCN$ expression may improve the anti-angiogenic and thrombotic changes observed within the placental vasculature in FGR. Moreover, the findings of this study have implications beyond pregnancy and suggest that $DCN$ may play important roles in the pathogenesis of other disease states in microvascular circulations through these angiogenic, thrombotic and growth factor mediated pathways.

In addition, investigation of the relative roles of the DCN protein core versus the GAG side chain in these functions may assist in revealing the logical therapeutic approaches to the treatment of FGR and related vascular pathologies.
Acknowledgements

a) The authors would like to thank Diagnostica Stago (Australia) for the loan of the Calibrated Automated Thrombogram.

b) Sources of funding: this work was supported by a National Health and Medical Research Council (NH&MRC) Project Grant, Australia (Application: 1004952).
References


Figure legends

Figure 1 Reduced DCN mRNA and protein expression following siRNA transfection in HMVECs

A. Real-time PCR was performed on HMVECs transfected with Mock and NC control, DCN siRNA1, 2, 3 and 4 oligonucleotides, over 24, 48 and 72 hours. Relative quantification of DCN mRNA expression relative to the housekeeping gene 18S rRNA was calculated using the 2-ΔΔCT method. * = Significance, p<0.05, n=18, One-Way ANOVA. The Y-axis represents the mRNA expression of decorin relative to 18S rRNA.

B. Protein was extracted from cultured HMVECs after transfection with Mock and NC control and DCN siRNA2 or siRNA3 oligonucleotides for 48 hours. Protein samples (25µg) were electrophoresed on a 10% SDS-PAGE gel and transferred to a PVDF membrane. Immunoblotting was performed and chemiluminescent detection of the 60kDa DCN protein is shown in the upper panel. Lanes 1, 2, 3 and 4 represents the Mock and NC control, DCN siRNA3 and siRNA4 transfected samples in HMVECs, respectively. The lower panel is GAPDH showing the protein load for all samples.

C. The densitometric values normalised to GAPDH for DCN immunoreactive protein after siRNA transfection in HMVECs is shown. * = Significance, p<0.05, n=3, One-Way ANOVA. The Y-axis represents the densitometric values of decorin protein relative to GAPDH.

Figure 2 Reduced DCN expression decreases HMVEC proliferation and network formation but increases thrombin generation

A. HMVEC proliferation was determined using xCELLigence (Roche Diagnostics, USA). A representative graph showing the cell index (Y-axis) of HMVECs transfected with Mock, NC, DCN siRNA2 or siRNA3 over a 72h time period is presented here.

B. The total effect of DCN gene reduction on HMVEC proliferation was determined quantitatively at the 48h time-point. * = Significance, p<0.05, n=18, One-Way ANOVA. The Y-axis represents the cell index over time.

C. Representative images of HMVEC network formation after 48h Mock, NC, and DCN siRNA2 or siRNA3 transfection. Cells were stained with calcien and images were taken using a fluorescent microscope (CellR, Olympus, Japan). Magnification of all images is at 100X, scale bars represent 50µm.

D. The ability for HMVECs to form networks after transfection with Mock, NC, DCN siRNA2 or siRNA3 over a 48h time period was determined using IBIDI angiogenesis slides (IBIDI, Germany). The total number of branch points was determined using the Wimasis Image Analysis tool. * = Significance, p<0.05, n=18, One-Way ANOVA. The Y-axis represents the number of branch points at 48h.

E. A representative thrombin generation curve showing the effect of DCN gene reduction in HMVECs is shown here. The Y-axis represents the amount of thrombin generated relative to time.

F. A statistical representation of the effect of reduced DCN expression on the ETP of HMVECs is shown. * = Significance, p<0.05, n=9, One-Way ANOVA. The Y-axis represents the amount of thrombin generated relative to time.
Figure 3 Identification of DCN downstream target genes after siRNA transfection

RNA was extracted from HMVECs transfected with DCN siRNA, transcribed into first strand cDNA, and the Taqman Growth Factors Real-time PCR array was performed for gene profiling. The 84 pre-dispensed genes, which included a panel of housekeeping genes, were amplified for 40 cycles of denaturation and primer extension. Gene expression values (fold change above or below threshold value of 2) were subsequently calculated for the DCN siRNA-treated plate, relative to the NC control and normalised to the housekeeping gene panel (x-axis). The red line shows the threshold value at 2 and the green line shows the threshold value at -2. Values greater than 2 were termed a fold increase and those less than -2 were considered a fold decrease.

Figure 4 Validation of candidate DCN downstream target genes in cultured HMVECs

cDNA from HMVECs transfected with Mock and NC controls, and DCN siRNA2 or siRNA3 were amplified for 40 cycles using pre-validated Taqman gene expression assays for FGF17 (A) and MSTN (B). The 18S rRNA housekeeping gene was used for relative quantification according to the 2^(-ΔΔCT) method of Livak and Schmittgen (2001). The NC control was used as the calibrator. * = Significance, p<0.05, n=9, One-Way ANOVA. The Y-axis represents the gene expression relative to 18S rRNA.

Figure 5 Expression of candidate target genes of DCN in HMVECs after reduction in DCN expression

The mRNA expression of VEGFA (A), MMP9 (B), EGFR (C), IGFR1 (D) and PLGF (E) was determined by real-time PCR using pre-validated Taqman gene expression assays. The 18S rRNA housekeeping gene was used for relative quantification according to the 2^(-ΔΔCT) method of Livak and Schmittgen (2001). The NC control was used as the calibrator. * = Significance, p<0.05, n=9, One-Way ANOVA. The Y-axis represents the gene expression relative to 18S rRNA.

Figure 6 Expression of DCN and its target genes in control and FGR-affected primary placental endothelial cells

The mRNA expression of DCN, EGFR1, IGFR1, PLGF, VEGFA and MMP9 was determined by real-time PCR according to the 2^(-ΔΔCT) method of Livak and Schmittgen (2001). The control PLECs were used as the calibrator. * = Significance, p<0.05, Mann-Whitney U Test. The Y-axis represents the gene expression relative to 18S rRNA.
Author Contributions

1. Chui, A – I declare that I participated in the study design, performing of all experiments, data analysis and interpretation, writing of manuscript and final approval of manuscript for submission.

2. Murthi, P - I declare that I participated in the study concept and design, performed the isolation of PLECs, interpretation of data, critical review of manuscript drafts and final approval of manuscript for submission.

3. Gunatillake, T – I declare that I participated in and performed some of the thrombin experiments, data analysis and interpretation, critical review and final approval of manuscript for submission.

4. Brennecke, SP – I declare that I participated in the study concept and design, interpretation of data, critical review of manuscript drafts and final approval of manuscript for submission.

5. Ignjatovic, V – I declare that I participated in the study concept and design, performed some of the thrombin experiments, interpretation and analysis of data, critical review of manuscript drafts and final approval of manuscript for submission.

6. Monagle, PT – I declare that I participated in the study concept and design, interpretation of data, critical review of manuscript drafts and final approval of manuscript for submission.

7. Whitelock, JM – I declare that I participated in the study concept and design, interpretation of data, critical review of manuscript drafts and final approval of manuscript for submission.

8. Said, JM – I declare that I participated in the study concept and design, interpretation of data, critical review of manuscript drafts and final approval of manuscript for submission.
Figure 1

A. Gene expression relative to 18S rRNA

B. Densitometry values relative to GAPDH

C. 

* Denotes statistically significant difference.
Figure 2

A. 

B. 

C. 

D. 

E. 

F.
Figure 3
Figure 4

A. FGF17

B. MSTN

Expression relative to 18S rRNA
Figure 5

A. VEGFA

B. MMP9

C. EGFR

D. IGFR1

E. PLGF

Expression relative to 18S rRNA
Figure 6

A. DCN PLEC

B. EGFR1 PLEC

C. IGFR1 PLEC

D. PLGF PLEC

E. VEGFA PLEC

F. MMP9 PLEC

Expression relative to 18S rRNA

Control PLEC | FGR PLEC

0.0 | 0.5 | 1.0 | 1.5 | 2.0

* indicates significant difference.
Altered Decorin Leads to Disrupted Endothelial Cell Function: A Possible Mechanism in the Pathogenesis of Fetal Growth Restriction?

Chui A 1, Murthi P 2,3, Gunatillake T 1,3, Brennecke S.P 2,3, Ignjatovic V 4,5,6, Monagle P.T 4,5,6, Whitelock J.M 7, and Said J.M 1

Supplementary Data

Materials and methods

Cell lines
The human microvascular endothelial cell line from neonatal foreskin (HMVEC) was a kind gift from A. Prof. Grant Drummond (Department of Pharmacology, Monash University). HMVECs were grown in Microvascular Endothelial Cell Growth Medium-2 (EGM-2 MV Single Quot Kit, catalogue number: CC-4147, Lonza/Clonetics, Victoria, Australia) containing 10% foetal bovine serum (FBS, Murdoch Children’s Research Institute Tissue Culture Supplies, Victoria, Australia).

Reduction of DCN expression by siRNA
Four independent DCN siRNA oligonucleotides were obtained as “4-For-Silencing siRNA Duplexes”™ (Qiagen, Victoria, Australia). The DCN siRNAs showed no significant DNA sequence similarity to other genes in GenBank cDNA databases (data not shown).

HMVECs were grown in EGM-2 MV and transfected with DCN siRNAs using HiPerfect transfection reagent (Qiagen, Victoria, Australia). Negative control (NC) siRNA consisted of a pool of enzyme-generated siRNA oligonucleotides of that were not specific for any known human genes (AllStars Negative siRNA, Qiagen, Victoria, Australia).

RNA extraction and cDNA preparation
Total RNA was extracted from cultured HMVECs using PureLink RNA Mini-kits (Lifesciences, Victoria, Australia), as per manufacturer’s instructions. Spectrophotometric analysis was used to determine the yield of total cellular RNA. Total cellular RNA was reverse-transcribed using Superscript III ribonuclease H-reverse transcriptase (Invitrogen, Victoria, Australia) and cDNA was prepared in a two-step reaction using 2µg of total RNA.

Real-Time PCR
Quantification of DCN mRNA expression was determined by real-time PCR in an ABI Prism 7700 (Perkin-Elmer-Applied Biosystems, Victoria, Australia) as described previously [1]. Real-time PCR was performed using inventoried assays that consisted of a mix of unlabelled gene-specific PCR primers and TaqMan FAM labelled MGB probes (Applied Biosystems, Victoria, Australia). Gene expression quantification for the housekeeping gene 18S rRNA MGB endogenous control (Applied Biosystems, Victoria, Australia) was performed in the same well and was calculated according to the 2^(-ΔΔCT) method [2].
Western Immunoblotting
Protein was homogenised and extracted from cultured HMVECs using RIPA Buffer (Pierce, Victoria, Australia). Immunoblotting was performed as described elsewhere [1]. An affinity purified rabbit monoclonal antibody for DCN (0.05µg/µl, Abcam, New South Wales, Australia), or rabbit monoclonal GAPDH (1ng/ml Imgenex, South Australia, Australia) was used as the primary antibody. Antibody binding was visualised using peroxidase-conjugated anti-rabbit or IgG-HRP secondary antibody (Dako, Victoria, Australia), following autoradiography using an enhanced chemiluminescence system (Amersham, New South Wales, Australia). The level of immunoreactive DCN protein relative to GAPDH was determined semi-quantitatively using scanning densitometry (Image Quant, New South Wales, Australia).

HMVEC cell growth using xCELLigence
HMVEC cell growth was assessed using the xCELLigence SP real-time system (Roche Diagnostics, Victoria, Australia) according to the manufacturer’s instructions. Briefly, cells were prepared and added to the E-Plate 96 (Roche Diagnostics, Victoria, Australia). The xCELLigence system recorded the background electrical impedance for 72h. The results were analysed using the RTCA Software 1.2 (Roche Diagnostics, Victoria, Australia) and GraphPad Prism 5 (GraphPad Software, California, USA).

HMVEC network formation assays
HMVEC network formation was assessed using the µ-Slide Angiogenesis system (IBIDI, Victoria, Australia). Briefly, µ-Slide Angiogenesis wells were coated with 10µl of neat Growth-Factor Reduced Matrigel™ (BD, Victoria, Australia) and allowed to polymerise for 1h at room temperature. HMVECs were then counted and resuspended in treatment media (media ± siRNA) and seeded at a density of 8000 cells in 50µl total volume per well. The slide was returned to the incubator for 48h. The media was then removed, stained with calcien-AM (Millipore, Victoria, Australia) and visualised under a fluorescent microscope. Photomicrographs of entire wells were taken in triplicates and branch points were counted by Wimasis Image Analysis.

Thrombin Generation Assays
HMVECs were plated into 96 well plates at a density of 5000 cells per well and transfected with DCN siRNAs and controls for 48h. Venous blood was collected from healthy blood donors (n=40) and Platelet Poor Plasma (PPP) was obtained. Measurement of endogenous thrombin potential (ETP) by Calibrated Automated Thrombogram (CAT, Thrombinscope, Stago Diagnostica, Victoria, Australia) was performed according to manufacturer’s instructions. All experiments were conducted in triplicate wells. The endogenous thrombin potential (ETP) represents the total enzymatic activity performed by thrombin and is generally considered the most predictive parameter of bleeding/thrombosis risk [3, 4]. The ETP (nM/minute) was calculated using the Thrombinscope software version 3.0.0.29 (Stago Diagnostica, Victoria, Australia) and represents the area under the thrombin generation curve.

Human Growth Factors PCR Array
The “Human Growth Factor” Taqman PCR array (Applied Biosystems, Victoria, Australia) for gene profiling was used to screen for downstream target genes of DCN,
according to manufacturer’s instructions. The plate contained 84 gene-specific primer sets and a panel of five housekeeping gene primers for normalisation (18S rRNA, B2M, HPRT1, GAPDH and ACTB). The relative gene expression values, or fold changes, were analysed using DataAssist Software v3.0 (Applied Biosystems, Victoria, Australia) and normalised to the average Ct value of the five housekeeping genes. Candidate genes were prioritised based on level of gene expression i.e. at least 2-fold change in mRNA expression in siRNA treated cells when compared with NC.

References